Vaginal estrogen tablets, moisturizers and placebo gel all can improve vaginal discomfort

March 19, 2018, Massachusetts General Hospital

A clinical trial comparing two treatments for postmenopausal vaginal discomfort - low-dose vaginal estrogen and a vaginal moisturizer - to placebo treatments found that both produced symptom improvements similar to those associated with the placebos after 12 weeks of treatment. The authors note that better understanding of the causes of postmenopausal symptoms could lead to more effective treatment options for this bothersome problem.

"The fact that all three treatments - vaginal estradiol tablets, a vaginal moisturizer and the gel we used as a - were able to reduce symptoms is great news for women, since it means that regular use of any of these treatments is likely to have benefit, whether the cost is $20 or $200," says Caroline Mitchell, MD, of the Massachusetts General Hospital (MGH) Department of Obstetrics and Gynecology, corresponding author of the report published online in JAMA Internal Medicine. "The significant impact of vaginal discomfort on the lives of women is reflected by how quickly we were able to enroll more than 300 participants - in less than a year. Women are desperate for some kind of intervention for these symptoms."

The authors, from seven research centers across the country, note that symptoms such as , itching and pain during sexual intercourse affect around half of postmenopausal women and can have negative quality-of-life effects similar to those of chronic conditions like arthritis or irritable bowel syndrome. But more than half of affected women use no medical treatments. Available nonprescription products, such as vaginal lubricants and moisturizers, can be messy; and prescription hormonal treatments in the form of creams, vaginal tablets and oral pills can be expensive and may raise concerns about safety.

The current study was designed to assess the effectiveness of the two most commonly recommended treatments - low-dose estrogen vaginal tablets and a nonhormonal vaginal moisturizer. At two clinical research sites - Kaiser Permanente Washington Health Research Institute in Seattle and the University of Minnesota in Minneapolis - the study enrolled 302 women, most between the ages of 55 and 64, who reported moderate to severe symptoms of vaginal itching, dryness, irritation or pain with sexual activity.

Participants were randomly divided into three groups—one receiving a low-dose vaginal estrogen and a placebo vaginal gel, one receiving a placebo vaginal tablet and the nonprescription vaginal moisturizer, and one receiving both placebo tablets and placebo gel. Participants were instructed to administer the vaginal tablet once a day for 2 weeks and then twice a week for the remaining 10 weeks of the study period. The moisturizing gels were to be applied every three days throughout the study period. Neither participants nor study staff knew to which group individual participants were assigned.

At the end of the study period all three groups had similar decreases in the severity of their most bothersome symptom. A similar proportion of women in each group had at least a 50 percent decrease in overall severity, which probably represents a clinically noticeable improvement. Improvement in sexual function and overall satisfaction were also similar across all three groups. There was a significantly higher positive response to the question, "Did you have a meaningful benefit from the treatment?" among those receiving the vaginal estrogen tablet than among those receiving the two placebos.

Mitchell notes that, while most studies of treatments for vaginal discomfort show a significant placebo effect, the size of the response to placebo treatments in this trial was surprising. "It's hard to say whether the properties of the placebo gel itself, which is an excellent lubricant, are responsible, but our results suggest that regular use of any one of these products may be helpful," she says. "During the 12 weeks of the trial, more than 90 percent of women used the medication regularly, but prior studies suggest that many women do not continue use of this type of treatment beyond 6 months. A remaining question is whether find the benefits of the treatment worthwhile enough to continue regular use." Mitchell is an assistant professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School.

Explore further: Oral probiotics have no impact on vaginal health in pregnancy

More information: Caroline M. Mitchell et al. Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms, JAMA Internal Medicine (2018). DOI: 10.1001/jamainternmed.2018.0116

Related Stories

Oral probiotics have no impact on vaginal health in pregnancy

November 1, 2016
(HealthDay)—For pregnant women, probiotics have no effect on vaginal health, according to a study published in the November issue of the American Journal of Obstetrics & Gynecology.

All vaginal estrogens effective for genitourinary sx of menopause

November 12, 2014
(HealthDay)—All vaginal estrogens are effective for women with genitourinary syndrome of menopause, according to a review published online Nov. 5 in Obstetrics & Gynecology.

Vaginal birth tied to later lack of pelvic organ support

March 14, 2018
(HealthDay)—Vaginal birth is associated with worse pelvic organ support five years after a woman's first delivery, and genital hiatus size is an independent predictor of worse support, according to a study published in ...

Vaginal estriol gel helps women recover after surgery for pelvic organ prolapse

March 29, 2017
Pelvic organ prolapse is estimated to affect up to one-half of all women, causing pain and interfering with sexual function. A new study demonstrates how an ultralow dose of vaginal estriol gel used before and after pelvic ...

pH-balanced vaginal gel doesn't improve dyspareunia

April 9, 2017
(HealthDay)—For breast cancer survivors who are premenopausal at diagnosis, a pH-balanced vaginal gel is no better than placebo for improving dyspareunia and overall sexual function, according to a study published in the ...

A new drug may help relieve menopausal vulvar and vaginal atrophy symptoms

April 3, 2016
A new low-dose vaginal estrogen capsule may help relieve symptoms of menopausal vulvar and vaginal atrophy, including dyspareunia (pain during sex), new industry-sponsored research reports. The study results will be presented ...

Recommended for you

New study reveals time and day women are most likely to give birth

June 15, 2018
A new study has found that the time and day that women give birth can vary significantly depending on how labour starts and the mode of giving birth.

Blood test for pregnant women can predict premature birth

June 7, 2018
A new blood test for pregnant women detects with 75-80 percent accuracy whether their pregnancies will end in premature birth. The technique can also be used to estimate a fetus's gestational age—or the mother's due date—as ...

Drug combination offers more effective care for patients suffering miscarriage

June 6, 2018
A combination of the drugs mifepristone and misoprostol can help bring closure to some women and their families suffering from miscarriage, and reduces the need for surgical intervention to complete the painful miscarriage ...

Genes, environment and schizophrenia—new study finds the placenta is the missing link

May 28, 2018
Hiding in plain sight, new research shines a spotlight on the placenta's critical role in the nature versus nurture debate and how it confers risk for schizophrenia and likely other neurodevelopmental disorders including ...

Vendors say pot eases morning sickness. Will baby pay a price?

May 22, 2018
(HealthDay)—Nearly 70 percent of Colorado marijuana dispensaries recommended pot products to manage early pregnancy-related morning sickness, new research reveals.

Pregnancy drug DES might have triggered ADHD in the grandchildren of women who used it

May 21, 2018
A study conducted by researchers at Columbia University's Mailman School of Public Health and Harvard T.H. Chan School of Public Health reported elevated odds for attention deficit hyperactivity disorder (ADHD) in the grandchildren ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.